BAUSCH HEALTH COMPANIES INC.

(BHC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Bausch Health Companies Inc. Announces New Post-Hoc Analysis of Pooled Results on the Safety and Efficacy of A Single Dose of Relistor Injection

12/22/2021 | 07:51am EDT

Bausch Health Companies Inc. announced that The Journal of Emergency Medicine has published a new post-hoc analysis of pooled results on the safety and efficacy of a single dose of RELISTOR injection in patients with severe illness and opioid-induced constipation who had insufficient response to laxative therapy. Entitled, "First Dose Efficacy of Methylnaltrexone in Patients with Severe Medical Illness and Opioid-Induced Constipation: A Pooled Analysis," the study results demonstrated that an initial dose of RELISTOR injection effectively produced rescue-free laxation (RFL) in greater proportions of severely ill patients with OIC compared to placebo (61.4% within 4 hours vs. 16%, and 72.1% within 24 hours vs.40.1%).OIC is prevalent among patients with advanced illness presenting to the emergency department. In particular, patients who are prescribed opioids for advanced illness who experience constipation have a significantly increased risk of emergency department visits, hospitalization rates, treatment costs and medical costs. The objective of this post hoc analysis of pooled results from three randomized, placebo- controlled trials was to assess the efficacy and safety of a single RELISTOR injection dose for OIC patients with severe medical illness, having insufficient response to laxative therapy and impairment of functional status. Per the study, there was no observable effect of RELISTOR injection treatment on the efficacy of opioid analgesia, indicating that pain control was maintained. Side effects of RELISTOR were mostly gastrointestinal in nature, including abdominal pain, flatulence, nausea, and vomiting, and declined from treatment day one to day two. In the clinical studies, the most common adverse reactions were: OIC in adult patients with chronic non-cancer pain o RELISTOR tablets: abdominal pain, diarrhea, headache, abdominal distention, vomiting, hyperhidrosis, anxiety, muscle spasms, rhinorrhe, and chills . o RELISTOR injection: abdominal pain, nausea, diarrhea, hyperhidrosis, hot flush, tremor, and chills . OIC in adult patients with advanced illness o RELISTOR injection: abdominal pain flatulence, nausea, dizziness, and diarrhea.


© S&P Capital IQ 2021
All news about BAUSCH HEALTH COMPANIES INC.
07:54aBausch + Lomb Receives Health Canada Approval of Lumify Redness Reliever Eye Drops
MT
07:01aBAUSCH + LOMB BRIEF : Receives Health Canada Approval of LUMIFY Redness Reliever Eye Drops
MT
05:47aBausch + Lomb Eye-Drop Product Gets Health Canada Approval
DJ
05/19Salix Pharmaceuticals To Share New Data At Digestive Disease Week 2022
AQ
05/18Bausch Health Says Salix Pharmaceuticals To Share New Data
MT
05/16Moody's Cuts Bausch Health's Senior Secured Ratings
MT
05/12TRANSCRIPT : Bausch Health Companies Inc. Presents at Goldman Sachs 7th Annual Leveraged F..
CI
05/11Inflation: Have we passed the peak yet?
05/11ANALYST RECOMMENDATIONS : Electronic Arts, Corning, Arrowhead Pharma, Tesla, Wynn Resorts...
05/11BAUSCH HEALTH COMPANIES INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
Analyst Recommendations on BAUSCH HEALTH COMPANIES INC.
More recommendations
Financials (USD)
Sales 2022 8 331 M - -
Net income 2022 -34,3 M - -
Net Debt 2022 19 398 M - -
P/E ratio 2022 -103x
Yield 2022 -
Capitalization 3 539 M 3 539 M -
EV / Sales 2022 2,75x
EV / Sales 2023 2,50x
Nbr of Employees 19 600
Free-Float 95,8%
Chart BAUSCH HEALTH COMPANIES INC.
Duration : Period :
Bausch Health Companies Inc. Technical Analysis Chart | BHC | CA0717341071 | MarketScreener
Technical analysis trends BAUSCH HEALTH COMPANIES INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 9,79 $
Average target price 30,80 $
Spread / Average Target 215%
EPS Revisions
Managers and Directors
Robert N. Power Chief Executive Officer & Director
Thomas J. Appio President & Co-Head-Bausch Lomb International
Sam A. Eldessouky CFO, Chief Accounting Officer, SVP & Controller
Joseph C. Papa Chairman
Tage Ramakrishna Chief Medical Officer, President-R&D
Sector and Competitors
1st jan.Capi. (M$)
BAUSCH HEALTH COMPANIES INC.-64.54%3 539
JOHNSON & JOHNSON4.89%472 179
PFIZER, INC.-10.45%296 704
ROCHE HOLDING AG-14.40%273 052
ELI LILLY AND COMPANY9.55%272 388
ABBVIE INC.9.33%261 585